These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 19300899

  • 1. Pantalone et al.: the risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Bell DS.
    Acta Diabetol; 2009 Jun; 46(2):155; author reply 157. PubMed ID: 19300899
    [No Abstract] [Full Text] [Related]

  • 2. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.
    Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
    [Abstract] [Full Text] [Related]

  • 3. Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).
    Erdmann E, Spanheimer R, Charbonnel B, PROactive Study Investigators.
    J Diabetes; 2010 Sep; 2(3):212-20. PubMed ID: 20923486
    [Abstract] [Full Text] [Related]

  • 4. Type 2 diabetes mellitus and heart failure.
    Choy CK, Rodgers JE, Nappi JM, Haines ST.
    Pharmacotherapy; 2008 Feb; 28(2):170-92. PubMed ID: 18225964
    [Abstract] [Full Text] [Related]

  • 5. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
    De Flines J, Scheen AJ.
    Rev Med Suisse; 2007 Aug 29; 3(122):1876, 1878-83. PubMed ID: 17896661
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.
    Walker AM, Koro CE, Landon J.
    Pharmacoepidemiol Drug Saf; 2008 Aug 29; 17(8):760-8. PubMed ID: 18383443
    [Abstract] [Full Text] [Related]

  • 8. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy.
    McAlister FA, Eurich DT, Majumdar SR, Johnson JA.
    Eur J Heart Fail; 2008 Jul 29; 10(7):703-8. PubMed ID: 18571471
    [Abstract] [Full Text] [Related]

  • 9. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A.
    Diabetes Metab Res Rev; 2009 Feb 29; 25(2):112-26. PubMed ID: 19219860
    [Abstract] [Full Text] [Related]

  • 10. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
    Cobitz A, Zambanini A, Sowell M, Heise M, Louridas B, McMorn S, Semigran M, Koch G.
    Pharmacoepidemiol Drug Saf; 2008 Aug 29; 17(8):769-81. PubMed ID: 18613278
    [Abstract] [Full Text] [Related]

  • 11. Metformin use and mortality among patients with diabetes and atherothrombosis.
    Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC, Goto S, Ravaud P, Marre M, Porath A, Bhatt DL, Steg PG, Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators.
    Arch Intern Med; 2010 Nov 22; 170(21):1892-9. PubMed ID: 21098347
    [Abstract] [Full Text] [Related]

  • 12. [Diabetes mellitus and heart failure: epidemiology and therapy].
    Pfister R, Erdmann E.
    Herz; 2008 Apr 22; 33(3):178-83. PubMed ID: 18568311
    [Abstract] [Full Text] [Related]

  • 13. Metformin use in decompensated heart failure.
    Boyd A, Nawarskas J.
    Cardiol Rev; 2008 Apr 22; 16(5):269-72. PubMed ID: 18708828
    [Abstract] [Full Text] [Related]

  • 14. Glucose-lowering therapy after myocardial infarction: more questions than answers.
    Radke PW, Schunkert H.
    Eur Heart J; 2008 Jan 22; 29(2):141-3. PubMed ID: 18199566
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Letter by Eller et al regarding article, "Lower mortality from coronary heart disease and stroke at higher altitudes in Switzerland".
    Eller K, Tancevski I, Eller P.
    Circulation; 2010 Apr 13; 121(14):e377. PubMed ID: 20385959
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Balancing risk and benefit with oral hypoglycemic drugs.
    Hamnvik OP, McMahon GT.
    Mt Sinai J Med; 2009 Jun 13; 76(3):234-43. PubMed ID: 19421967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.